Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,080.36
+5.68 (+0.53%)
Official Closing Price
Updated: 7:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
99
100
Next >
Is There a Future for Viking Therapeutics?
↗
November 09, 2025
The weight loss drug company was counted out far too early in the summer, but investors are warming to it again.
Via
The Motley Fool
Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump
↗
November 09, 2025
The companies announced a huge deal that will have implications for investors.
Via
The Motley Fool
Topics
World Trade
Organon (OGN) Reports Earnings Tomorrow: What To Expect
November 08, 2025
Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Monday before market hours. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
Eli Lilly And These AI Plays Lead 5 Stocks Near Buy Points
↗
November 08, 2025
Eli Lilly stock and a pair of AI plays lead this watch list of stocks near buy points as the S&P 500 makes a stand at a key support level.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Stocks
Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices
↗
November 06, 2025
Via
Stocktwits
Topics
Government
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years?
↗
November 06, 2025
Via
Stocktwits
This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy
↗
November 08, 2025
The stock didn't stay down for too long.
Via
The Motley Fool
Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030
↗
November 08, 2025
It could become the first trillion-dollar pharmaceutical company in the process.
Via
The Motley Fool
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.
↗
November 08, 2025
Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.
Via
The Motley Fool
Topics
Government
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance
↗
November 08, 2025
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."
Via
Benzinga
S&P 500: The Bull Market Is Just Getting Started
November 07, 2025
The S&P 500 has been on an impressive ascent, with market sentiment in November 2025 largely skewed towards cautious optimism. After a robust year of gains, driven significantly by the "mania around...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Energy
Why Novo Nordisk Stock Is Sinking This Week
↗
November 07, 2025
The global drugmaker is facing some headwinds related to tough competition.
Via
The Motley Fool
Topics
Government
World Trade
Why Nvidia (NVDA) Stock Is Falling Today
November 07, 2025
Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) fell 4.1% in the afternoon session after the stock retreated amid renewed concerns about stretched valuations in the AI space and...
Via
StockStory
Topics
Artificial Intelligence
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment
↗
November 07, 2025
Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.
Via
Benzinga
Navigating the Shifting Tides: Experts Chart Course for 2025 Stock Market
November 07, 2025
As the calendar turns towards late 2025, leading financial experts are providing a detailed compass for investors, navigating a stock market characterized by cautious optimism, elevated valuations, and...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
World Trade
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included
↗
November 07, 2025
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.
Via
Benzinga
Eli Lilly’s Weight-Loss Drug Mounjaro Becomes India’s Top-Selling Medicine By Value: Report
↗
November 07, 2025
The drug has surpassed GlaxoSmithKline’s antibiotic Augmentin, according to a Reuters report on Friday, citing data from research firm Pharmarack.
Via
Stocktwits
Topics
Government
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
↗
November 07, 2025
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.
Via
Investor's Business Daily
Topics
Government
Eli Lilly Stock Defies Trump’s GLP-1 Pricing Pressure With 6-Day Rally As Wall Street Cheers FDA Boost And New Weight-Loss Drug Data
↗
November 06, 2025
Bank of America Securities called Lilly’s GLP-1 pricing deal “probably a good tradeoff overall,” keeping a ‘Buy’ rating and $950 target.
Via
Stocktwits
Topics
Government
World Trade
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced
↗
November 06, 2025
Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage.
Via
Stocktwits
Topics
Government
World Trade
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts
↗
November 06, 2025
Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.
Via
Benzinga
Topics
Government
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
↗
November 06, 2025
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.
Via
Benzinga
Topics
Government
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
↗
November 06, 2025
Is the fourth time the charm for this Danish pharmaceutical giant?
Via
The Motley Fool
Topics
Earnings
Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo
↗
November 06, 2025
The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs.
Via
Investor's Business Daily
Topics
Government
Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns
November 06, 2025
The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
November 06, 2025
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....
Via
MarketMinute
Topics
Intellectual Property
My 6 Top-Ranked Stocks to Buy Right Now in November
↗
November 06, 2025
Whether you're looking for AI stocks or dividend stocks, there is something for everyone in this list.
Via
The Motley Fool
Topics
Artificial Intelligence
Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes
↗
November 06, 2025
A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration.
Via
Benzinga
Topics
Government
Dow Jumps Over 200 Points: Investor Sentiment Improves, Fear & Greed Index Remains In 'Extreme Fear' Zone
↗
November 06, 2025
The CNN Fear & Greed Index eased, but remained in Extreme Fear zone on Wed. Stocks rose on solid earnings & speculation of Fed rate cut.
Via
Benzinga
Topics
Economy
Stocks
1 Mid-Cap Stock for Long-Term Investors and 2 We Question
November 05, 2025
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...
Via
StockStory
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.